22May

Treatment with Saxenda® for three years reduced the risk of developing type 2 di ... Read more

20May

Janssen Biotech Inc. acquires licence from Novo Nordisk for a development progra ... Read more

08May

New data demonstrated Saxenda® provides benefits beyond weight loss ... Read more

04May

Novo Nordisk invests DKK 1.5 billion in new haemophilia treatment manufacturing ... Read more

20May

Novo Nordisk A/S - Share repurchase programme ... Read more

11May

Novo Nordisk A/S - Share repurchase programme ... Read more

30April

Increased operating profit in Danish kroner by 73% in the first quarter of 2015 ... Read more

29April

Total number of voting rights and share capital in Novo Nordisk A/S as of 29 Apr ... Read more

27May

Helvea Healthcare Trip, Zurich

02June

Jefferies Global Healthcare Conference, New York

07June

ADA investor presentation, Boston

09June

Goldman Sachs Annual Global Healthcare Conference, Rancho Palos Verdes

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
IR material


Download relevant Investor Relations material

 
Financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



Annual report


Download the Novo Nordisk Annual Report



Contacts



Subscriptions


Sign up and follow Novo Nordisk Investors Relations



Q1 2015 release


Access key information on the Q1 2015 release